Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Bristol-Myers shareholders approve Celgene takeover

Written by: | no-reply@reuters.com | Dated: Friday, April 12th, 2019

 

Bristol-Myers says shareholders vote to approve Celgene takeover

 

NEW YORK (Reuters) – Bristol-Myers Squibb Co’s shareholders voted to approve the drugmaker’s $74 billion takeover of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

The company said investors holding 75.7 percent of its shares had voted in favor of the deal in a preliminary count.

Celgene said separately in a statement that its shareholders representing more than 70 percent of its shares outstanding who were entitled to vote, voted in favor of the transaction.

It also said it expects the deal to close in the third quarter.

Bristol-Myers announced in early January that it planned to buy Celgene in a cash and stock transaction to bring together companies that specialize in oncology and cardiovascular drugs in what would be the largest pharmaceutical industry merger ever.

But Starboard and the company’s second largest shareholder, Wellington Management, opposed the deal. Starboard abandoned a campaign against the deal after proxy advisory firms recommended investors support it.

Bristol-Myers said during a shareholders meeting that it does not expect changes to its dividend policy after the acquisition.

 

Reporting by Michael Erman and Svea Herbst-Bayliss, writing by Caroline Humer; Editing by Chizu Nomiyama and Bill Berkrot

 

Reuters source:

https://www.reuters.com/article/us-celgene-m-a-bristol-myers/bristol-myers-says-shareholders-vote-to-approve-celgene-takeover-idUSKCN1RO1T3

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom